Recursion Pharmaceuticals (RXRX) Other Non-Current Assets (2020 - 2026)

Recursion Pharmaceuticals' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• Quarterly Other Non-Current Assets fell 7.69% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 7.69% YoY) and the FY2025 annual result came in at $6.0 million, down 31.64% from the prior year.
• Other Non-Current Assets was $5.2 million for Q1 2026 at Recursion Pharmaceuticals, down from $6.0 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $9.4 million in Q2 2025 and bottomed at $36000.0 in Q1 2022.
• A 5-year average of $6.1 million and a median of $6.6 million in 2023 frame the typical range for Other Non-Current Assets.
• Peak annual rise in Other Non-Current Assets reached 23197.14% in 2022, while the deepest fall reached 98.83% in 2022.
• Recursion Pharmaceuticals' Other Non-Current Assets stood at $7.9 million in 2022, then retreated by 16.3% to $6.6 million in 2023, then jumped by 33.13% to $8.8 million in 2024, then plunged by 31.64% to $6.0 million in 2025, then retreated by 13.87% to $5.2 million in 2026.
• Business Quant data shows RXRX's Other Non-Current Assets at $5.2 million in Q1 2026, $6.0 million in Q4 2025, and $4.2 million in Q3 2025.